Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Glycosaminoglycan (GAG) biosynthesis enzymes comprise a diverse set of Golgi-resident proteins, including xylosyltransferases, galactosyltransferases, and various glycosyltransferases (e.g., EXT1, EXT2, CHSY1) that assemble long, unbranched polysaccharide chains [1][2]. These enzymes are responsible for the production of essential molecules like heparan sulfate, chondroitin sulfate, and dermatan sulfate, which are critical for extracellular matrix (ECM) integrity and the regulation of growth factor signaling [3]. Genetic mutations in these biosynthetic pathways result in a spectrum of disorders known as mucopolysaccharidoses (MPS) and skeletal dysplasias, characterized by the toxic accumulation of GAG precursors or structural defects in connective tissue [4]. In the context of cancer, these enzymes are often upregulated, facilitating tumor growth and metastasis by altering the tumor microenvironment [5]. Therapeutic targeting of this pathway includes substrate reduction therapies, such as the use of Odiparcil, which acts as a decoy substrate to reduce the synthesis of pathological GAGs in MPS patients [6]. Additionally, small molecule inhibitors targeting specific sulfotransferases are being explored to modulate inflammatory responses and viral entry, as many pathogens utilize surface GAGs for host cell attachment [7]. Sources: [1] KEGG Pathway map00532/map00534; [2] UniProt Glycosyltransferase family; [3] Nature (2007) 446:1030-1037; [4] Mol Genet Metab (2021) 132:S1; [5] FEBS J (2012) 279:1177-1197; [6] Inventiva Pharma Pipeline; [7] Antiviral Res (2004) 64:1-10.
Substrate reduction therapy (SRT) through the use of decoy substrates to divert biosynthetic flux, and competitive inhibition of specific glycosyltransferases or sulfotransferases to modulate GAG chain length and sulfation patterns.
4 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Glycosaminoglycan biosynthesis enzymes (GAG biosynthesis enzymes).